{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:09:15Z","timestamp":1792098555963,"version":"4.4.0"},"reference-count":102,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2022,1,2]]},"DOI":"10.1080\/13543776.2021.1965991","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T07:04:01Z","timestamp":1628492641000},"page":"13-28","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["A patent review of aldosterone synthase inhibitors (2014-present)"],"prefix":"10.1080","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5971-5057","authenticated-orcid":false,"given":"Jun","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, Roche Innovation Center Shanghai, Roche Pharma Research and Early Development, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-1870","authenticated-orcid":false,"given":"Xiao","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Roche Innovation Center Shanghai, Roche Pharma Research and Early Development, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7629-2255","authenticated-orcid":false,"given":"Xuefei","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Roche Innovation Center Shanghai, Roche Pharma Research and Early Development, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpaa137"},{"key":"cit0002","volume-title":"Physiology, aldosterone","author":"Scott JH","year":"2021"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2012.09.004"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2014.04.006"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.4158\/EP14551.RA"},{"key":"cit0006","volume-title":"Hypoaldosteronism","author":"Rajkumar V","year":"2021"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e328360c200"},{"issue":"3","key":"cit0008","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cphy.c130044","author":"Gomez-Sanchez E","year":"2014","journal-title":"Compr Physiol"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2015.07.006"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190222145116"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190222144359"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283455ca5"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-020-1023-y"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01073-5"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-020-01399-7"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"cit0017","unstructured":"NDAF. 2021. Accessed 15 July 2021. Available from: https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2021."},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/bs.vh.2018.12.001"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010716-104651"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.2174\/1389450119666180326125926"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-005-2343-3"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs388"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.9"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.521625"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105332"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.2174\/1568026611313120003"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/bs.vh.2018.10.002"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1210\/en.2017-00637"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(90)81190-Y"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2016.1151873"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000226183.98439.b3"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.157271"},{"issue":"2","key":"cit0033","first-page":"296","volume":"19","author":"Wang HZ","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2117"},{"key":"cit0035","volume-title":"LFF269: a cortisol-sparing CYP11B2 inhibitor that lowers aldosterone in human subjects","author":"Papillon J"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07716"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1177\/1470320317717883"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1021\/jm401430e"},{"key":"cit0039","unstructured":"Balestra M, Burke J, Chen Z, et al., inventors; Boehringer Ingelheim International GmbH, assignee. Naphthyridines, azaindoles and related compounds as aldosterone synthase inhibitors and their preparation patent. US20140323468. 2014."},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.236463"},{"key":"cit0041","unstructured":"Hornberger KR, Meyers KM, Nemoto PA, et al., inventors; Boehringer Ingelheim International GmbH, assignee. Preparation of heteroaryl compounds as aldosterone synthase inhibitors patent. WO2016061161. 2016."},{"key":"cit0042","unstructured":"Chen Z, Cogan D, Guo X, et al., inventors; Boehringer Ingelheim International GmbH, assignee. Preparation of pyranopyridine as aldosterone synthase inhibitors patent. WO2016089800. 2016."},{"key":"cit0043","unstructured":"Burke J, Cogan D, Lord J, et al., inventors; Boehringer Ingelheim International GmbH, assignee. Pyranoimidazolones as aldosterone synthase inhibitors and their preparation patent. WO2016014736. 2016."},{"key":"cit0044","unstructured":"Balestra M, Bentzien JM, Burke J, et al., inventors; Boehringer Ingelheim International GmbH, assignee. Preparation of fused isoxazole compounds as aldosterone synthase inhibitors and therapeutic uses thereof patent. WO2016123275. 2016."},{"key":"cit0045","unstructured":"McKibben BP, Meyers KM, Zhang Y, et al., inventors; Boehringer Ingelheim International GmbH, assignee. Preparation of bicyclic imidazole derivatives as selective aldosterone synthase inhibitors useful for treatment of renal disease, cardiovascular diseases and fibrotic disorders patent. WO2018005177. 2018."},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2017.12.015"},{"key":"cit0047","unstructured":"Hoyt SB, Park MK, London C, et al., inventors; Merck Sharp & Dohme Corp., assignee. Preparation of benzimidazole derivatives as aldosterone synthase inhibitors patent. WO2012012478. 2012."},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.5b00054"},{"key":"cit0049","unstructured":"Hoyt SB, Petrilli WL, London C, et al., inventors; Merck Sharp & Dohme Corp. ElexoPharm GmbH, assignee. Triazoloquinoline derivatives as aldosterone synthase inhibitors and their preparation patent. WO2012148808. 2012."},{"key":"cit0050","unstructured":"Bennett DJ, Cai J, Carswell E, et al., inventors; Merck Sharp & Dohme Corp., assignee. Preparation of pyrazolopyridine compounds as aldosterone synthase inhibitors patent. WO2013043521. 2013."},{"key":"cit0051","unstructured":"Bennett DJ, Cai J, Carswell E, et al., inventors; Merck Sharp & Dohme Corp., assignee. Pyrazolopyridyl compounds as aldosterone synthase inhibitors patent. US20140288094. 2014."},{"key":"cit0052","unstructured":"Bennett DJ, Cai J, Carswell E, et al., inventors; Merck Sharp & Dohme Corp., assignee. Preparation of triazolopyridine compounds as aldosterone synthase inhibitors patent. WO2013043520. 2013."},{"key":"cit0053","unstructured":"Bennett DJ, Cai J, Carswell E, et al., inventors; Merck Sharp & Dohme Corp. Jubilant Organosys Limited, assignee. Triazolopyridyl compounds as aldosterone synthase inhibitors patent. US20140228396. 2014."},{"key":"cit0054","unstructured":"Ali A, Bennett DJ, Cai J, et al., inventors; Merck Sharp & Dohme Corp., assignee. Imidazopyridyl compounds as aldosterone synthase inhibitors patent. WO2013043518. 2013."},{"key":"cit0055","unstructured":"Ali A, Bennett DJ, Cai J, et al., inventors; Merck Sharp & Dohme Corp., assignee. Imidazopyridyl compounds as aldosterone synthase inhibitors patent. US9173873. 2015."},{"key":"cit0056","unstructured":"Ali A, Lo MM-C, Metzger E, et al. inventors; Merck Sharp & Dohme Corp. ElexoPharm GmbH, assignee. Indoline compounds as aldosterone synthase inhibitors related applications patent. WO2014055595. 2014."},{"key":"cit0057","unstructured":"Hoyt SB, Taylor JA, London C, et al., inventors; Merck Sharp & Dohme Corp., assignee. Indazole compounds as aldosterone synthase inhibitors patent. WO2014099833. 2014."},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2017.04.021"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.12.003"},{"key":"cit0060","unstructured":"Ali A, Bey E, Hartmann R, et al. inventors; Merck Sharp & Dohme Corp. ElexoPharm GmbH, assignee. Tricyclic triazole aldosterone synthase inhibitors and their therapeutic use patent. WO2013151876. 2013."},{"key":"cit0061","unstructured":"Ali A, Bey E, Hartmann R, et al., inventors; Merck Sharp & Dohme Corp. Elexopharm GmbH, assignee. Aldosterone synthase inhibitors patent. US20150306091. 2015."},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00079"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.5b00048"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.6b00455"},{"key":"cit0065","unstructured":"Ushirogochi H, Sasaki W, Onda Y, et al., inventors; Mitsubishi Tanabe Pharma Corporation, assignee. Disubstituted 1,2,4-triazine compound and its use for pharmaceutical composition and method for prevention or treatment of diseases or symptoms involving aldosterone patent. WO2015163427. 2015."},{"key":"cit0066","unstructured":"Sakakibara R, Ushirogochi H, Sasaki W, et al., inventors; Mitsubishi Tanabe Pharma Corporation, assignee. Preparation of nitrogen-containing aromatic heterocyclic compounds having inhibitory activity on aldosterone synthase patent. WO2017069226. 2017."},{"key":"cit0067","unstructured":"Sakakibara R, Sasaki W, Yamaguchi M, et al., inventors; Mitsubishi Tanabe Pharma Corporation, assignee. Preparation of nitrogen-containing heterocyclic compounds as aldosterone synthase inhibitors patent. WO2017170765. 2017."},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00328"},{"key":"cit0069","unstructured":"Ksander GM, Meredith E, Monovich LG, et al., inventors; Novartis A.G. Novartis Pharma G.m.b.H., assignee. Preparation of condensed imidazole derivatives for the inhibition of aldosterone synthase and aromatase patent. WO2007024945. 2007."},{"key":"cit0070","unstructured":"Papillon J, Ksander GM, Hu Q-Y, inventors; Novartis A.G. Novartis Pharma G.m.b.H., assignee. Preparation of tetrahydroimidazo[1,5-a]pyrazine derivatives as aldosterone synthase and\/or 11\u03b2-hydroxylase inhibitors patent. WO2007139992. 2007."},{"key":"cit0071","unstructured":"Hu Q-Y, Ksander GM, inventors; Novartis AG, assignee. Preparation of 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives as aldosterone\/11\u03b2-hydroxylase inhibitors patent. WO2008076860. 2008."},{"key":"cit0072","unstructured":"Adams C, Hu Q-Y, McGuire LW, et al., inventors; Novartis AG, assignee. Preparation of pyridinylindole derivatives for use as aldosterone synthase modulators patent. WO2009156462. 2009."},{"key":"cit0073","unstructured":"Chamoin S, Hu Q-Y, Papillon J, inventors; Novartis AG, assignee. Preparation of aryl pyridine as aldosterone synthase inhibitors patent. WO2010130796. 2010."},{"key":"cit0074","unstructured":"Adams CM, Chamoin S, Hu Q-Y, inventors; Novartis AG, assignee. Preparation of 5-(pyridin-3-yl)-1,3-dihydroindol-2-one derivatives as modulators of aldosterone synthase and\/or CYP11B1 patent. WO2010130794. 2010."},{"key":"cit0075","unstructured":"Herold P, Mah R, Tschinke V, et al., inventors; Novartis AG Speedel Experimenta AG, assignee. Heterocyclic spiro-compounds as aldosterone synthase inhibitors patent. US8071774. 2011."},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1021\/ml400324c"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00407"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01545"},{"key":"cit0079","unstructured":"Aebi J, Amrein K, Hornsperger B, et al., inventors; Hoffmann-La Roche Inc., assignee. Preparation of phenyl-tetrahydroisoquinoline derivatives useful in the treatment of disease patent. US20130274287. 2013."},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00851"},{"key":"cit0081","unstructured":"Aebi J, Amrein K, Britton R, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of phenyldihydropyridine derivatives for use as aldosterone synthase inhibitors patent. WO2015055602. 2015."},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1039\/C6OB00848H"},{"key":"cit0083","unstructured":"Aebi J, Amrein K, Fantasia SM, et al., inventors; F. Hoffmann-La Roche AG, assignee. Preparation of bicyclic dihydroquinoline-2-one derivatives as CYP11B2 and CYP11B1 inhibitors for therapy patent. WO2013041591. 2013."},{"key":"cit0084","unstructured":"Aebi J, Amrein K, Hornsperger B, et al., inventors; F. Hoffmann-La Roche AG, assignee. Preparation of dihydroquinolinone derivatives for use as CYP11B2 or CYP11B1 inhibitors patent. WO2013037779. 2013."},{"key":"cit0085","unstructured":"Aebi J, Amrein K, Hornsperger B, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of dihydroquinoline-2-one derivatives that are aldosterone synthase inhibitors useful in therapy and prophylaxis of primary aldosteronism, cushing syndrome and other diseases patent. WO2014139981. 2014."},{"key":"cit0086","unstructured":"Aebi J, Amrein K, Hornsperger B, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of dihydroquinolin-2-one derivatives as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors patent. WO2014135561. 2014."},{"key":"cit0087","unstructured":"Aebi J, Amrein K, Hornsperger B, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of pyrazolyl dihydroquinolinones as aldosterone synthase inhibitors useful in therapy patent. WO2016066662. 2016."},{"key":"cit0088","unstructured":"Aebi J, Amrein K, Hornsperger B, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of pyrazolyl-3,4-dihydroquinolin-2-one as aldosterone synthase inhibitors useful in therapy patent. WO2016066663. 2016."},{"key":"cit0089","unstructured":"Aebi J, Amrein K, Chen W, et al., inventors; F. Hoffmann-La Roche AG, assignee. New bicyclic dihydroisoquinolin-1-one derivatives as aldosterone synthase inhibitors and their preparation patent. WO2013079452. 2013."},{"key":"cit0090","unstructured":"Aebi J, Amrein K, Chen W, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of new 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydroisoindol-1-one compounds as aldosterone synthase inhibitors patent. WO2014191336. 2014."},{"key":"cit0091","unstructured":"Aebi J, Amrein K, Chen W, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of new 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydroisoindol-1-one compounds as aldosterone synthase inhibitors patent WO2014191338. 2014."},{"key":"cit0092","unstructured":"Aebi J, Amrein K, Chen W, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of new 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydroisoindol-1-one compounds as aldosterone synthase inhibitors patent. WO2014191340. 2014."},{"key":"cit0093","unstructured":"Aebi J, Amrein KE, Chen J, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of spirodiamine derivatives as aldosterone synthase inhibitors patent. WO2016055394. 2016."},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00233"},{"key":"cit0095","unstructured":"Sparks S, Yates CM, Shaver SR, et al., inventors; Viamet Pharmaceuticals (Bermuda), Ltd., assignee. Preparation of pyridazinyl benzimidazoles and related nitrogen heterocycles as metalloenzyme inhibitors for the treatment of diseases patent. WO2018125800. 2018."},{"key":"cit0096","unstructured":"Sparks S, Yates CM, Shaver SR, inventors; Viamet Pharmaceuticals (Bermuda), Ltd., assignee. Preparation of pyrimidinyl benzimidazoles and related nitrogen heterocycles as metalloenzyme inhibitors for the treatment of diseases patent. WO2018125799. 2018."},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00152"},{"key":"cit0098","unstructured":"Panicker B, Oehlen LJWM, inventors; Angion Biomedica Corp, assignee. Preparation of benzothiazolyl pyridyl alkanols for reducing aldosterone patent. WO2016109492. 2016."},{"key":"cit0099","unstructured":"Kliuchenovich AV, Strushkevich NV, Gilep AA, inventors; Obshchestvo s Ogranichennoi Otvetstvennostiu \u201cTarget Medikals,\u201d assignee. Aldosterone synthase inhibitors based on 2-amino-4h-pyran-3-carbonitrile derivatives patent. RU2717310. 2020."},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1210\/me.2012-1287"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.006214"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000557"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2021.1965991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T18:41:23Z","timestamp":1642444883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2021.1965991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,2]]}},"alternative-id":["10.1080\/13543776.2021.1965991"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2021.1965991","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}